Literature DB >> 10623762

Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts.

J Hansen1, K Qing, H J Kwon, C Mah, A Srivastava.   

Abstract

Although adeno-associated virus type 2 (AAV) has gained attention as a potentially useful alternative to the more commonly used retrovirus- and adenovirus-based vectors for human gene therapy, efficient gene transfer and transgene expression by AAV vectors require that the following two obstacles be overcome. First, the target cell must express the receptor and the coreceptor for AAV infection, and second, the cell must allow for viral second-strand DNA synthesis. We now describe a third obstacle, impaired intracellular trafficking of AAV to the nucleus, which results in the lack of transgene expression in murine fibroblasts which do express the AAV receptor and the coreceptor and which are permissive for viral second-strand DNA synthesis. We document that AAV vectors bind efficiently and gain entry successfully into NIH 3T3 cells, but trafficking into the nucleus is significantly impaired in these cells. In contrast, viral trafficking to the nucleus in cells known to be efficiently transduced by AAV vectors is both rapid and efficient. The demonstration of yet another obstacle in AAV-mediated gene transfer has implications for the optimal use of these vectors in human gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623762      PMCID: PMC111620          DOI: 10.1128/jvi.74.2.992-996.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  Development of adeno-associated virus vectors for gene therapy of cystic fibrosis.

Authors:  B J Carter; T R Flotte
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

Review 2.  Adeno-associated virus 2-mediated transduction and erythroid lineage-specific expression in human hematopoietic progenitor cells.

Authors:  A Srivastava; X S Wang; S Ponnazhagan; S Z Zhou; M C Yoder
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.

Authors:  D D Koeberl; I E Alexander; C L Halbert; D W Russell; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector.

Authors:  T J McCown; X Xiao; J Li; G R Breese; R J Samulski
Journal:  Brain Res       Date:  1996-03-25       Impact factor: 3.252

6.  Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors.

Authors:  I E Alexander; D W Russell; A M Spence; A D Miller
Journal:  Hum Gene Ther       Date:  1996-05-01       Impact factor: 5.695

7.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

Authors:  P D Kessler; G M Podsakoff; X Chen; S A McQuiston; P C Colosi; L A Matelis; G J Kurtzman; B J Byrne
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection.

Authors:  S Ponnazhagan; X S Wang; M J Woody; F Luo; L Y Kang; M L Nallari; N C Munshi; S Z Zhou; A Srivastava
Journal:  J Gen Virol       Date:  1996-06       Impact factor: 3.891

9.  Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells.

Authors:  G V Sperinde; M A Nugent
Journal:  Biochemistry       Date:  1998-09-22       Impact factor: 3.162

10.  Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus.

Authors:  B Sodeik; M W Ebersold; A Helenius
Journal:  J Cell Biol       Date:  1997-03-10       Impact factor: 10.539

View more
  62 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Benefits of recombinant adeno-associated virus (rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis.

Authors:  Anja Weimer; Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Janina Frisch; Anna Wezel; Jochen Jung; Dieter Kohn; Ernest F Terwilliger; Stephen B Trippel; Magali Cucchiarini
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

3.  High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy.

Authors:  Mengxin Li; Giridhara R Jayandharan; Baozheng Li; Chen Ling; Wenqin Ma; Arun Srivastava; Li Zhong
Journal:  Hum Gene Ther       Date:  2010-10-06       Impact factor: 5.695

4.  The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different.

Authors:  Susanne I Lang; Stephanie Boelz; Alexandra Y Stroh-Dege; Jean Rommelaere; Christiane Dinsart; Jan J Cornelis
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.

Authors:  Ziying Yan; Diana C M Lei-Butters; Xiaoming Liu; Yulong Zhang; Liang Zhang; Meihui Luo; Roman Zak; John F Engelhardt
Journal:  J Biol Chem       Date:  2006-08-09       Impact factor: 5.157

6.  rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion.

Authors:  Wei Ding; Liang N Zhang; Charles Yeaman; John F Engelhardt
Journal:  Mol Ther       Date:  2006-01-25       Impact factor: 11.454

Review 7.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

Review 8.  AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

Authors:  Zongchao Han; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-10       Impact factor: 4.799

9.  An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells.

Authors:  Jae-Hyung Jang; James T Koerber; Jung-Suk Kim; Prashanth Asuri; Tandis Vazin; Melissa Bartel; Albert Keung; Inchan Kwon; Kook In Park; David V Schaffer
Journal:  Mol Ther       Date:  2011-01-11       Impact factor: 11.454

10.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.